Whatever happened to immunotoxins? Research, and hope, are still alive.
Holzman
David C
DC
D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000276:immunology / Q000494:pharmacology*; D017277:Drug Approval; D004345:Drug Industry; D004357:Drug Synergism; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology*; D000922:Immunotoxins / Q000276:immunology / Q000494:pharmacology*; D007376:Interleukin-2 / Q000276:immunology / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007155:Immunologic Factors; D000922:Immunotoxins; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox